A detailed history of Neuberger Berman Group LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 158,630 shares of ARVN stock, worth $4.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158,630
Previous 151,245 4.88%
Holding current value
$4.1 Million
Previous $4.03 Million 2.96%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $174,729 - $241,711
7,385 Added 4.88%
158,630 $3.91 Million
Q2 2024

Nov 14, 2024

BUY
$24.46 - $40.4 $2.32 Million - $3.83 Million
94,875 Added 168.31%
151,245 $4.03 Million
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $2.32 Million - $3.83 Million
94,875 Added 168.31%
151,245 $4.03 Million
Q1 2024

Nov 14, 2024

SELL
$36.38 - $52.31 $13,969 - $20,087
-384 Reduced 0.68%
56,370 $2.33 Million
Q1 2024

May 13, 2024

BUY
$36.38 - $52.31 $2.05 Million - $2.95 Million
56,370 New
56,370 $2.33 Million
Q4 2023

Nov 14, 2024

SELL
$14.19 - $42.33 $1.34 Million - $4 Million
-94,491 Reduced 62.48%
56,754 $2.34 Million
Q4 2023

Feb 09, 2024

SELL
$14.19 - $42.33 $551,650 - $1.65 Million
-38,876 Reduced 40.65%
56,754 $2.34 Million
Q3 2023

Nov 14, 2023

SELL
$19.64 - $28.21 $1.35 Million - $1.94 Million
-68,862 Reduced 41.86%
95,630 $1.88 Million
Q2 2023

Aug 11, 2023

BUY
$21.73 - $31.43 $3.57 Million - $5.17 Million
164,492 New
164,492 $4.08 Million
Q2 2020

Aug 13, 2020

BUY
$29.88 - $56.74 $1.58 Million - $3.01 Million
53,000 New
53,000 $1.78 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.38B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.